Literature DB >> 23811241

Hepatitis B and C in African Americans: current status and continued challenges.

Kimberly A Forde1, Orapin Tanapanpanit2, K Rajender Reddy3.   

Abstract

Viral hepatitis remains a public health concern in the United States, resulting in excess morbidity and mortality for the individual and representing a burden to societies as evidenced by billions of dollars in health care expenditures. As with many chronic diseases, race and ethnicity influence various aspects of disease pathogenesis, including mechanisms of persistence, disease progression, disease sequelae, and response to therapy. For hepatitis B and C infections, African Americans disproportionately bear a large burden of disease in the United States. The role and importance of African American race, however, have been less well-characterized in the literature among the population of viral hepatitis-infected individuals. The differences in epidemiology, manifestations of liver disease, response to therapy, and differential trends in liver transplantation in African Americans compared with other racial and ethnic groups deserve special attention. This review will address the current status of hepatitis B and C infection in African Americans in the United States and identify some of the remaining challenges in diagnosis, characterization of natural history, and treatment. For the purposes of this review, the terms African American and black will be used interchangeably throughout the text.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African American; Black; Disparities; Hepatitis B; Hepatitis C

Mesh:

Year:  2013        PMID: 23811241      PMCID: PMC3947744          DOI: 10.1016/j.cgh.2013.06.006

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  98 in total

1.  Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994.

Authors:  Geraldine M McQuillan; Deanna Kruszon-Moran; Benny J Kottiri; Lester R Curtin; Jacqueline W Lucas; Raynard S Kington
Journal:  Am J Public Health       Date:  2004-11       Impact factor: 9.308

2.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

3.  Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis.

Authors:  Michael C Kew
Journal:  World J Hepatol       Date:  2010-02-27

4.  Durability of serologic response after lamivudine treatment of chronic hepatitis B.

Authors:  Jules L Dienstag; Janusz Cianciara; Selim Karayalcin; Kris V Kowdley; Bernard Willems; Stanilav Plisek; Mary Woessner; Stephen Gardner; Eugene Schiff
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 5.  Is chronic hepatitis B being undertreated in the United States?

Authors:  C Cohen; S D Holmberg; B J McMahon; J M Block; C L Brosgart; R G Gish; W T London; T M Block
Journal:  J Viral Hepat       Date:  2010-12-08       Impact factor: 3.728

6.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.

Authors:  G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

7.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

8.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  20 in total

1.  Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon.

Authors:  Kazuaki Jindai; Courtney Crawford; Ann R Thomas
Journal:  Public Health Rep       Date:  2018-12-03       Impact factor: 2.792

2.  Insulin Resistance and Metabolic Syndrome: Clinical and Laboratory Associations in African Americans Without Diabetes in the Hemochromatosis and Iron Overload Screening Study.

Authors:  James C Barton; Jackson Clayborn Barton; Ronald T Acton
Journal:  Metab Syndr Relat Disord       Date:  2018-05-31       Impact factor: 1.894

3.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

4.  Establishing the link between hepatitis B virus infection and colorectal adenoma.

Authors:  Brijesh B Patel; Seth Lipka; Huafeng Shen; Ashley H Davis-Yadley; Prakash Viswanathan
Journal:  J Gastrointest Oncol       Date:  2015-10

5.  Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.

Authors:  Veronica Wendy Setiawan; Daniel O Stram; Jacqueline Porcel; Shelly C Lu; Loïc Le Marchand; Mazen Noureddin
Journal:  Hepatology       Date:  2016-07-17       Impact factor: 17.425

6.  Hepatitis B Virus Screening and Vaccination in First-generation African Immigrants: A Pilot Study.

Authors:  Olorunseun O Ogunwobi; Omar Dibba; Lin Zhu; Adeodat Ilboudo; Yin Tan; Marilyn A Fraser; Grace X Ma
Journal:  J Community Health       Date:  2019-12

7.  Increasing Viral Hepatitis Knowledge Among Urban Ethnic Minority Youth: Findings from a Community Based Prevention Intervention.

Authors:  Ijeoma Opara; David T Lardier; Andriana Herrera; Pauline Garcia-Reid; Robert J Reid
Journal:  J Community Health       Date:  2020-04

8.  Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care.

Authors:  Lisa I Backus; Pamela S Belperio; Timothy P Loomis; Larry A Mole
Journal:  Am J Public Health       Date:  2014-09       Impact factor: 9.308

Review 9.  Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations.

Authors:  Zaki A Sherif; Armana Saeed; Shima Ghavimi; Seyed-Mehdi Nouraie; Adeyinka O Laiyemo; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2016-04-01       Impact factor: 3.199

10.  Differential Expression of MicroRNAs in Hepatitis C Virus-Mediated Liver Disease Between African Americans and Caucasians: Implications for Racial Health Disparities.

Authors:  Pradip B Devhare; Robert Steele; Adrian M Di Bisceglie; David E Kaplan; Ratna B Ray
Journal:  Gene Expr       Date:  2016-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.